Aimei Health Technology Co., Ltd. SEC 10-Q Report

Aimei Health Technology Co., Ltd., a blank check company incorporated in the Cayman Islands, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational activities, focusing on its efforts to enter into a business combination within the healthcare innovation sectors, including biopharmaceuticals, medical technology, and diagnostics.

Financial Highlights

• Net Income: $184,662, driven by interest income earned on assets held in the Trust Account of $598,076, offset by formation and operational costs of $413,414.
• Basic and diluted net income per ordinary shares subject to possible redemption: $0.03, reflecting the allocation of net income to redeemable shares.
• Basic and diluted net income per share, ordinary shares attributable to not subject to possible redemption: $0.03, consistent with the net income allocation.

Business Highlights

• Business Overview: Aimei Health Technology Co., Ltd. is a blank check company focused on entering into a business combination with one or more businesses, particularly targeting healthcare innovation sectors such as biopharmaceuticals, medical technology, and diagnostics.
• Proposed Business Combination: The company has entered into a definitive Business Combination Agreement with United Hydrogen Group Inc. and related entities, aiming to merge and form a new entity, Pubco, which will be a wholly-owned subsidiary. This agreement is subject to customary closing conditions and regulatory approvals.
• Operational Activities: The company's activities have been primarily focused on organizational tasks, preparing for the IPO, and identifying potential target companies for a business combination. No operational revenue has been generated as the company is still in the pre-business combination phase.
• Future Outlook: The company is actively working towards completing its initial business combination by June 6, 2025, following multiple extensions. Management is focused on identifying and evaluating prospective business combination candidates and is prepared to use funds held outside the Trust Account for related expenses.
• Segment Information: The company operates as a single segment, with its Chief Financial Officer reviewing the overall performance to make resource allocation decisions. The focus is on managing formation and operating costs and maximizing interest income from the Trust Account.
• Going Concern Consideration: There is substantial doubt about the company's ability to continue as a going concern if it fails to complete a business combination within the specified timeframe, which would require ceasing operations and liquidating the Trust Account.

SEC Filing: Aimei Health Technology Co., Ltd. [ AFJK ] - 10-Q - May. 14, 2025